THE IMPACT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) ON SERUM LIPID PROFILE IN HEMODIALYSIS (HD) PATIENTS

被引：0
|
作者：
Arita, Kazuko [1 ]
Tanabe, Takehiro [1 ]
Kihara, Emi [1 ]
Maeda, Katsutoshi [1 ]
Oda, Hiroaki [1 ]
Doi, Shigehiro [2 ]
Masaki, Takao [2 ]
机构：
[1] Oda Naika Clin, Hiroshima, Japan
[2] Hiroshima Univ Hosp, Hiroshima, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP719
引用
收藏
页码：293 / 293
页数：1
相关论文
共 50 条
  • [41] Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes
    Trico, Domenico
    Raggi, Francesco
    Distaso, Mariarosaria
    Ferrannini, Ele
    Solini, Anna
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 190
  • [42] PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IS ASSOCIATED WITH LP(A) IN TYPE 2 DIABETIC PATIENTS
    Nekaies, Y.
    Baudin, B.
    Sakly, M.
    Attia, N.
    ATHEROSCLEROSIS, 2015, 241 (01) : E102 - E102
  • [43] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Sun, Huimin
    Meng, Wen
    Zhu, Jie
    Wang, Lu
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (06) : 643 - 658
  • [44] SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN NON-DIABETIC ASIANS WITH NEPHROTIC SYNDROME
    Lim, Cynthia
    Mok, Irene
    Tan, Hui Zhuan
    Teng, Esther W. L.
    Chue, Xiu Ping
    Ang, Wei Mian
    Chin, Yok Mooi
    Foo, Marjorie
    Choo, Jason
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 758 - 758
  • [45] IDENTIFICATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FROM NATURAL PRODUCTS
    Hirata, Hiroshi
    Kontani, Ami
    Takazumi, Koji
    Segawa, Shuichi
    Tsuchiya, Youichi
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 1175 - 1175
  • [46] Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
    Sharotri, Vikas
    Collier, Daniel M.
    Olson, Diane R.
    Zhou, Ruifeng
    Snyder, Peter M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (23) : 19266 - 19274
  • [47] Managed Care Pharmacist Updates for Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
    Patel, Jeenal
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (04): : S76 - S82
  • [48] The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
    Marston, Nicholas A.
    Gurmu, Yared
    Melloni, Giorgio E. M.
    Bonaca, Marc
    Gencer, Baris
    Sever, Peter S.
    Pedersen, Terje R.
    Keech, Anthony C.
    Roselli, Carolina
    Lubitz, Steven A.
    Ellinor, Patrick T.
    O'Donoghue, Michelle L.
    Giugliano, Robert P.
    Ruff, Christian T.
    Sabatine, Marc S.
    CIRCULATION, 2020, 141 (20) : 1600 - 1607
  • [49] The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
    Ben Zadok, O. Itzhaki
    Mager, A.
    Leshem-Lev, D.
    Lev, E.
    Kornowski, R.
    Eisen, A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1828 - 1828
  • [50] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Huimin Sun
    Wen Meng
    Jie Zhu
    Lu Wang
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 643 - 658
12345